Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Gastrointestinal 2Breast 2Myeloid 1

Conditions

Myelodysplastic Syndromes 25Leukemia, Myeloid, Acute 24Myeloproliferative Disorders 17Leukemia, Myelogenous, Chronic, BCR-ABL Positive 15Polycythemia Vera 9Primary Myelofibrosis 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Leukemia, Myeloid, Chronic-Phase 4Leukemia 4Thrombocythemia, Essential 3Lymphohistiocytosis, Hemophagocytic 3Leukemia, Myelomonocytic, Chronic 3Hematologic Neoplasms 3Hematologic Diseases 3Recurrence 2Polycythemia 2Myelodysplastic-Myeloproliferative Diseases 2Motor Activity 2Lymphoproliferative Disorders 2Lymphoma, Non-Hodgkin 2Lymphoma 2Epstein-Barr Virus Infections 2VEXAS syndrome 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Thrombophilia 1Thrombocytosis 1Thrombocytopenia 1Polycythemia, primary familial and congenital 1Pleural Effusion, Malignant 1

Interventions

venetoclax 1tagraxofusp 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Pathologic Complete Response × Myeloid × Clear all
NCT07007052 2025-11-26

TAGVEN

French Innovative Leukemia Organisation

Phase 2 Not yet recruiting
33 enrolled
Myeloid

Pathologic Complete Response, Blastic Plasmacytoid Dendritic Cell Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡